AUSTEDO Drug Patent Profile

When do Austedo patents expire, and when can generic versions of Austedo launch?

Austedo is a drug marketed by Teva Branded Pharm and Teva and is included in two NDAs. There are fifteen patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and thirty patent family members in thirty-four countries.

The generic ingredient in AUSTEDO is deutetrabenazine. One supplier is listed for this compound. Additional details are available on the deutetrabenazine profile page.

DrugPatentWatch^® Generic Entry Outlook for Austedo

Austedo was eligible for patent challenges on April 3, 2021.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for AUSTEDO

International Patents:	130
US Patents:	14
Applicants:	2
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	12
Clinical Trials:	4
Patent Applications:	18
Drug Prices:	Drug price information for AUSTEDO
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for AUSTEDO
What excipients (inactive ingredients) are in AUSTEDO?	AUSTEDO excipients list
DailyMed Link:	AUSTEDO at DailyMed

See drug prices for AUSTEDO

Recent Clinical Trials for AUSTEDO

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Vanderbilt University Medical Center	Phase 2/Phase 3
Teva Branded Pharmaceutical Products R&D, Inc.	Phase 2/Phase 3
Fundacion Huntington Puerto Rico	Phase 1

See all AUSTEDO clinical trials

Paragraph IV (Patent) Challenges for AUSTEDO

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
AUSTEDO	Tablets	deutetrabenazine	6 mg, 9 mg and 12 mg	208082	2	2021-04-05

US Patents and Regulatory Information for AUSTEDO

AUSTEDO is protected by fourteen US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva	AUSTEDO XR	deutetrabenazine	TABLET, EXTENDED RELEASE;ORAL	216354-008	Jul 1, 2024		RX	Yes	No	11,813,232*PED				Y
Teva	AUSTEDO XR	deutetrabenazine	TABLET, EXTENDED RELEASE;ORAL	216354-004	May 29, 2024		RX	Yes	No	11,357,772*PED				Y
Teva Branded Pharm	AUSTEDO	deutetrabenazine	TABLET;ORAL	208082-003	Apr 3, 2017		RX	Yes	Yes	11,357,772*PED				Y
Teva Branded Pharm	AUSTEDO	deutetrabenazine	TABLET;ORAL	208082-003	Apr 3, 2017		RX	Yes	Yes	9,550,780*PED				Y
Teva	AUSTEDO XR	deutetrabenazine	TABLET, EXTENDED RELEASE;ORAL	216354-003	Feb 17, 2023		RX	Yes	No	9,550,780*PED				Y
Teva	AUSTEDO XR	deutetrabenazine	TABLET, EXTENDED RELEASE;ORAL	216354-005	May 29, 2024		RX	Yes	No	12,016,858*PED				Y
Teva	AUSTEDO XR	deutetrabenazine	TABLET, EXTENDED RELEASE;ORAL	216354-001	Feb 17, 2023		RX	Yes	No	10,959,996*PED				Y

International Patents for AUSTEDO

When does loss-of-exclusivity occur for AUSTEDO?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

European Patent Office

Hong Kong

India

Japan

New Zealand

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering AUSTEDO around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	6362601
European Patent Office	3596077	ANALOGUES DE DEUTÉTRABÉNAZINE, LEUR PRÉPARATION ET LEUR UTILISATION (ANALOGS OF DEUTETRABENAZINE, THEIR PREPARATION AND USE)
Japan	5970037
Japan	7608050
Serbia	63647	POSTUPCI ZA LEČENJE POREMEĆAJA ABNORMALNIH NEVOLJNIH POKRETA (METHODS FOR THE TREATMENT OF ABNORMAL INVOLUNTARY MOVEMENT DISORDERS)
Chile	2019002629
South Africa	201902108	METHODS FOR THE TREATMENT OF ABNORMAL INVOLUNTARY MOVEMENT DISORDERS

AUSTEDO: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

AUSTEDO (deutetrabenazine), marketed by Teva Pharmaceutical Industries Ltd., is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor. It is approved for the treatment of chorea associated with Huntington’s disease and tardive dyskinesia. This report analyzes AUSTEDO's market position, competitive landscape, and projected financial performance.

What is AUSTEDO's Current Market Position?

AUSTEDO is a leading treatment option for its approved indications. Its efficacy in reducing involuntary movements associated with Huntington’s disease and tardive dyskinesia has established a significant market share. The drug's mechanism of action, targeting VMAT2, differentiates it from other therapeutic approaches, particularly in the management of these complex neurological conditions.

The market for treatments for Huntington’s disease is relatively niche, driven by a specific genetic disorder. Tardive dyskinesia, while potentially linked to a broader range of antipsychotic medications, also represents a defined patient population with unmet needs. AUSTEDO's success is underpinned by its ability to offer a targeted and effective solution in these areas.

Key market drivers for AUSTEDO include:

• Increasing diagnosis rates: Greater awareness and diagnostic capabilities for both Huntington’s disease and tardive dyskinesia contribute to an expanding patient pool.
• Unmet medical needs: Prior to AUSTEDO, treatment options for chorea in Huntington’s disease and tardive dyskinesia were limited, often focusing on symptom management with significant side effects.
• Physician adoption: Clinical data supporting AUSTEDO's efficacy and safety profile has led to its widespread adoption by neurologists and psychiatrists.
• Payer coverage: Favorable reimbursement policies and formulary placement by major payers are critical for market access and patient affordability.

AUSTEDO’s market penetration is further supported by Teva’s commercialization strategy, which includes targeted physician education and patient support programs.

What is the Competitive Landscape for AUSTEDO?

The competitive landscape for AUSTEDO is characterized by both direct and indirect competitors.

Direct Competitors

The primary direct competitor to AUSTEDO is Ingrezza (valbenazine), developed by Neurocrine Biosciences. Both Ingrezza and AUSTEDO are VMAT2 inhibitors approved for tardive dyskinesia and are considered interchangeable by many clinicians.

Drug Name	Company	Mechanism of Action	Approved Indications	Approximate Launch Date
AUSTEDO	Teva Pharmaceuticals	VMAT2 Inhibitor	Huntington's Disease (Chorea), Tardive Dyskinesia	2017 (US)
Ingrezza	Neurocrine Biosciences	VMAT2 Inhibitor	Tardive Dyskinesia, Chorea (Huntington's Disease - 2023)	2017 (US)

Source: Company reports, FDA approvals.

The approval of Ingrezza for chorea associated with Huntington’s disease in November 2023 directly expands its competitive scope against AUSTEDO, intensifying the rivalry in this indication.

Indirect Competitors

Indirect competition arises from:

• Off-label use of other medications: Historically, older medications such as tetrabenazine (Xenazine) have been used, although often with a less favorable side effect profile.
• Symptomatic treatments: Medications that manage symptoms without directly targeting the underlying mechanism, such as dopaminergic blockers, may be used in certain patient populations, though they do not address the core motor symptoms of chorea.
• Emerging therapies: Research and development in neurological disorders is ongoing, and new therapeutic modalities could emerge in the future, potentially disrupting the market.

The key differentiator between AUSTEDO and Ingrezza often comes down to physician preference, patient response, side effect profiles, and commercial factors such as pricing and patient assistance programs. Teva's patent strategy for AUSTEDO is also a significant factor in its long-term competitive advantage.

What are the Key Patents Protecting AUSTEDO?

AUSTEDO is protected by a portfolio of patents covering its composition of matter, formulation, and methods of use. The intellectual property landscape is crucial for maintaining market exclusivity and pricing power.

Key patent families for AUSTEDO include patents related to:

• Composition of Matter: Patents covering the deutetrabenazine molecule itself. These are typically the strongest patents, providing broad protection.
• Formulation: Patents describing specific pharmaceutical compositions, including excipients, dosage forms, and stability characteristics.
• Methods of Use: Patents claiming the use of deutetrabenazine for treating specific conditions, such as Huntington’s disease and tardive dyskinesia.
• Polymorphs and Manufacturing Processes: Patents related to specific crystalline forms of the active pharmaceutical ingredient (API) or novel manufacturing routes, which can extend market exclusivity.

United States Patent 9,707,403 (issued August 8, 2017) is a significant patent covering certain deutetrabenazine compounds and their use in treating movement disorders. While specific expiration dates for all patents are proprietary and subject to complex legal nuances, U.S. patents generally have a term of 20 years from the filing date, subject to potential extensions such as patent term adjustments (PTA) and patent term extensions (PTE) for regulatory delays.

Teva has actively defended its intellectual property against generic challenges. Litigation surrounding AUSTEDO patents is a critical aspect of its financial trajectory. Generic manufacturers typically seek to invalidate existing patents or demonstrate non-infringement. Successful challenges can lead to earlier market entry for generics, significantly impacting AUSTEDO's revenue.

The development of AUSTEDO XR, a once-daily extended-release formulation, also provides a pathway for extending market exclusivity beyond the expiration of original patents. Patents covering AUSTEDO XR would offer protection for this newer iteration of the drug.

What is AUSTEDO's Financial Trajectory and Revenue Generation?

AUSTEDO has demonstrated strong revenue growth since its launch, becoming a significant contributor to Teva’s overall financial performance.

Revenue Data:

• 2020: AUSTEDO net sales were approximately $1.4 billion.
• 2021: Net sales reached approximately $1.7 billion.
• 2022: Net sales increased to approximately $1.9 billion.
• 2023: Teva reported AUSTEDO and AUSTEDO XR net sales of approximately $2.03 billion [1].

This consistent year-over-year growth highlights the drug's market success and its role in offsetting declines in Teva's generics business. The upward trend is attributable to increasing patient adoption, physician prescribing, and effective market access strategies.

Factors Influencing Future Revenue:

• Patent Expiration and Generic Competition: The most significant factor impacting AUSTEDO's future revenue is the eventual loss of market exclusivity due to patent expiration. As key patents approach expiration, generic manufacturers will seek FDA approval for their own versions. The timeline for generic entry is subject to patent litigation outcomes and regulatory review. Teva has implemented strategies, including the AUSTEDO XR formulation, to defend against or delay generic competition.
• Pricing Power: As a branded specialty pharmaceutical, AUSTEDO commands premium pricing. However, increasing scrutiny of drug pricing by payers and governments, coupled with the introduction of generics, can exert downward pressure on prices.
• Market Penetration and Patient Access: Continued growth will depend on further penetrating the existing patient populations for Huntington's disease and tardive dyskinesia, as well as expanding access for new diagnoses. Teva's patient assistance programs play a role in ensuring affordability.
• Lifecycle Management: The development and commercialization of AUSTEDO XR represent an example of lifecycle management to extend the drug's commercial life and potentially capture additional market share through improved patient convenience.
• Competitive Dynamics: The success of Ingrezza and any potential future VMAT2 inhibitors will continue to influence AUSTEDO's market share and pricing power.

Analyst Projections:

While specific forward-looking analyst projections are subject to frequent revision and competitive intelligence, general market sentiment indicates AUSTEDO is expected to remain a significant revenue generator for Teva in the near to medium term. However, the pace of revenue growth is likely to moderate as patent challenges and potential generic entry loom. Analysts will closely monitor patent litigation outcomes and the company's ability to effectively manage its product lifecycle.

What are the Regulatory and Clinical Considerations for AUSTEDO?

AUSTEDO’s journey from development to market and its ongoing commercialization are governed by rigorous regulatory and clinical considerations.

Regulatory Approvals

AUSTEDO received its initial U.S. Food and Drug Administration (FDA) approval for chorea associated with Huntington's disease on April 3, 2017. Subsequently, it gained FDA approval for tardive dyskinesia on April 10, 2017. These approvals were based on extensive clinical trial data demonstrating efficacy and safety.

The drug also holds approvals in other major markets, including the European Union and Canada, under different brand names in some regions (e.g., COUDEXA in the EU). Regulatory pathways in different jurisdictions can vary in their timelines and requirements.

Clinical Efficacy and Safety Profile

Clinical trials for AUSTEDO demonstrated statistically significant reductions in the objective assessment of involuntary movements in patients with Huntington’s disease and tardive dyskinesia. Common adverse events reported in clinical trials included somnolence, fatigue, insomnia, and depression.

• Huntington’s Disease: The primary efficacy endpoint in the pivotal Phase 3 study (TELLUS) was the change from baseline in the Unified Huntington's Disease Rating Scale (UHDRS) total motor score.
• Tardive Dyskinesia: The pivotal Phase 3 study (Dr. S. K. Chadi, et al.) used the Abnormal Involuntary Movement Scale (AIMS) to assess efficacy.

Post-marketing surveillance continues to monitor the safety profile of AUSTEDO in broader patient populations. Any emerging safety signals could lead to label changes, warnings, or, in rare cases, regulatory action.

Post-Marketing Commitments and Studies

Regulatory bodies may require post-marketing studies as a condition of approval. These studies can investigate long-term safety, effectiveness in specific subpopulations, or compare the drug to other treatments. Teva continues to conduct research and gather data to support AUSTEDO's ongoing use and to explore potential new indications or formulations.

Generic Competition and Regulatory Pathways

The pathway for generic drug approval in the U.S. is governed by the Hatch-Waxman Act. Generic manufacturers must demonstrate bioequivalence to the reference listed drug (RLD), which is AUSTEDO in this case. The FDA reviews these applications, and upon approval, the generic drug can enter the market, often leading to significant price erosion for the branded product. Teva’s patent portfolio and strategic legal challenges are crucial in managing the timeline of generic entry.

What are the Strategic Implications for Teva Pharmaceuticals?

AUSTEDO is a critical asset for Teva Pharmaceuticals, contributing significantly to its specialty medicines segment and overall profitability. Its success has been instrumental in Teva's strategic pivot towards higher-margin branded products.

Key Strategic Implications:

• Revenue Diversification: AUSTEDO provides a substantial and growing revenue stream that helps diversify Teva's business away from a sole reliance on generics. This reduces exposure to pricing pressures and market access challenges prevalent in the generics sector.
• Specialty Pharma Focus: The strong performance of AUSTEDO reinforces Teva's commitment to its specialty pharmaceuticals business. This strategy involves investing in R&D for novel therapies and acquiring promising late-stage assets.
• Intellectual Property Defense: Teva's aggressive defense of AUSTEDO's patents is a strategic imperative. Successful patent protection is essential for maximizing revenue during the exclusivity period and delaying generic competition. The outcome of patent litigation directly impacts Teva's future financial projections.
• Product Lifecycle Management: The introduction of AUSTEDO XR demonstrates Teva's strategic approach to product lifecycle management. By offering an improved formulation with once-daily dosing, Teva aims to enhance patient convenience, potentially increase market share, and create a new revenue stream that may have its own patent protection, further extending market exclusivity.
• Competitive Positioning: AUSTEDO's market leadership in its indications strengthens Teva's position in the neurology and movement disorders therapeutic areas. This can create opportunities for future pipeline development and partnerships in related fields.
• Financial Stability and Investment: The consistent revenue generated by AUSTEDO provides Teva with financial stability, enabling it to invest in its R&D pipeline, pursue strategic acquisitions, and manage its debt obligations.

The long-term strategic value of AUSTEDO hinges on Teva's ability to effectively manage its patent cliff, fend off generic competition, and continue to innovate through lifecycle management and potential new indications.

Key Takeaways

• AUSTEDO (deutetrabenazine) is a leading VMAT2 inhibitor for Huntington’s disease chorea and tardive dyskinesia, generating over $2 billion in annual revenue for Teva Pharmaceuticals.
• Its primary competitor is Ingrezza (valbenazine), also a VMAT2 inhibitor, which has expanded its competitive reach by gaining approval for Huntington’s disease chorea.
• AUSTEDO's market exclusivity is protected by a portfolio of patents, but these will eventually expire, paving the way for generic competition.
• Teva has implemented lifecycle management strategies, including the development of AUSTEDO XR, to extend market exclusivity and maintain revenue streams.
• AUSTEDO is a cornerstone of Teva's specialty pharmaceuticals business, providing significant revenue diversification and financial stability.

Frequently Asked Questions

What is the primary mechanism of action for AUSTEDO?

AUSTEDO is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor. It works by reducing the uptake of monoamines (such as dopamine) into presynaptic vesicles, thereby decreasing the release of dopamine in the brain. This reduction in dopamine activity is thought to alleviate the involuntary movements characteristic of Huntington's disease chorea and tardive dyskinesia.

How does AUSTEDO XR differ from the original AUSTEDO formulation?

AUSTEDO XR is an extended-release formulation designed for once-daily dosing, whereas the original AUSTEDO requires twice-daily dosing. The XR formulation aims to improve patient convenience and adherence by simplifying the dosing regimen. Teva's strategy behind AUSTEDO XR is to further leverage its intellectual property and extend market exclusivity.

What is the expected impact of generic competition on AUSTEDO sales?

The introduction of generic versions of AUSTEDO is expected to lead to a significant decline in its sales revenue. Generic drugs typically enter the market at substantially lower prices than their branded counterparts, eroding market share and pricing power for the originator product. The timing and magnitude of this impact will depend on patent litigation outcomes and the specific launch dates of generic products.

Are there any other approved indications for AUSTEDO besides Huntington's disease and tardive dyskinesia?

As of the latest available information, AUSTEDO is approved in the United States for the treatment of chorea associated with Huntington’s disease and tardive dyskinesia. Teva may be exploring or have initiated clinical trials for other potential indications, but these are not currently approved uses.

What are the main side effects associated with AUSTEDO?

Common side effects reported with AUSTEDO include somnolence (sleepiness), fatigue, insomnia, and depression. Patients and healthcare providers should discuss the full range of potential side effects, contraindications, and warnings as outlined in the drug's prescribing information.

---

Citations

[1] Teva Pharmaceutical Industries Ltd. (2024, February 8). Teva Announces Fourth Quarter and Full Year 2023 Results. [Press Release]. https://ir.tevapharm.com/news-releases/news-release-details/teva-announces-fourth-quarter-and-full-year-2023-results